Artículos de Revistas

URI permanente para esta colección

https://hdl.handle.net/20.500.12254/7370

Examinar

Examinando Artículos de Revistas por Autor "Baudrand, Rene"

Mostrando 1 - 2 de 2
  • Miniatura
    Ítem
    Driving hypertension: non-classic apparent mineralocorticoid excess
    (Springer Nature, 2025-11-12) Carvajal, Cristian A.; Tapia-Castillo, Alejandra; Uslar, Thomas; Vaidya, Anand; Pérez, Jorge A.; Baudrand, Rene; Fardella, Carlos E.
    Non-classic apparent mineralocorticoid excess is an underrecognized cause of low-renin hypertension, which is often misdiagnosed as essential hypertension. This condition challenges traditional classifications and highlights the need for mechanism-based diagnostics and medical care. Hypertension remains a leading contributor to global cardiovascular morbidity and mortality. It has a high prevalence, low rate of identifiable causes and is frequently resistant to conventional therapy. Hypertension is traditionally classified as ‘essential’ and multifactorial; however, up to one-third of patients have hypertension with a low-renin phenotype . This subtype has been largely attributed to primary aldosteronism, yet emerging data suggest a broader and more complex spectrum of mineralocorticoid receptor (MR) overactivation. Non-classic apparent mineralocorticoid excess (NC-AME) is one of several overlooked contributors to low-renin hypertension; NC-AME might account for a meaningful proportion of patients who have been misclassified as having essential hypertension.
  • Miniatura
    Ítem
    Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study
    (Elsevier, 2026-06-27) Uslar, Thomas; Sanfuentes, Benjamín; Olmos, Roberto; Burnier, Alberth; Böhm, Pauline; Guarda, Francisco J.; Huete, Álvaro; Mertens, Nicolás; Besa, Cecilia; Andía, Marcelo; Majerson, Alejandro; Cartes, Jaime; Tapia-Castillo, Alejandra; Carvajal, Cristian A.; Fardella, Carlos E.; Allende, Fidel; Solari, Sandra; Vaidya, Anand; Baudrand, Rene
    Background: Incidental adrenal adenomas are common, yet renin status is infrequently assessed in hypertensive patients. Emerging evidence supports a spectrum of renin-independent aldosterone excess associated with adverse cardiovascular risk. Objective and methods: To determine the frequency of a low-renin phenotype in a prospective cohort of hypertensive patients with adrenal adenomas and to evaluate the clinical response to aldosterone-targeted therapy across baseline aldosterone categories. Low-renin phenotype was defined as suppressed renin (PRA <1.0 ng/mL/ h or DRC <10 μIU/mL). Among these patients, plasma aldosterone concentration (PAC) was categorized as 5–10 ng/dL (Group 1), 10–15 ng/dL (Group 2), and >15 ng/dL (Group 3). Patients with suppressed renin were treated with MR antagonists or adrenalectomy and followed longitudinally using PAMO/PASO criteria. Results: Low renin was present in 47% (138/290) of hypertensive patients. Increasing aldosterone levels were associated with higher systolic blood pressure (SBP), resistant hypertension, higher antihypertensive treatment burden, lower potassium, and reduced eGFR (p-trend <0.001). After a mean follow-up of 24±18 months (n = 121), aldosterone-targeted therapy (75% medical, 25% surgical) led to significant reductions in SBP (-18, -26, and -30 mmHg across Groups 1–3; all p < 0.001), decreased medication and significant increases in renin (all p < 0.001), irrespective of aldosterone category. Conclusions: Nearly half of hypertensive patients with adrenal incidentalomas exhibit suppressed renin levels associated with greater blood pressure burden and favorable response to aldosterone-targeted therapy, even in lower aldosterone levels categories. These findings support systematic renin assessment in hypertensive patients with incidental adrenal adenomas and provide a rationale for testing aldosterone-targeted therapy in broader hypertensive populations beyond adrenal adenomas